Galmed Pharmaceuticals (GLMD) surged 85% pre-market after unveiling a new brain-penetrating formulation of its drug Aramchol. This treatment is designed to cross the blood-brain barrier to potentially treat Parkinson's disease. The move follows a 27% gain over five sessions, pushing the stock above $1 for the first time since December.